Unlocking the role of B cells in chronic brain inflammation
A new study in the Annals of Clinical and Translational Neurology investigates the impact of the B-cell depleting therapy ocrelizumab on paramagnetic rim lesions (PRLs), a subset of chronic active lesions in multiple sclerosis. Using quantitative susceptibility mapping (QSM), researchers tracked 97 PRLs in 29 patients. Before treatment, these lesions, characterized by iron-laden macrophages and microglia, showed higher iron content. Following ocrelizumab administration, a significant reduction in iron susceptibility within PRLs was observed, suggesting the monoclonal antibody may attenuate the underlying smoldering inflammation associated with these specific lesions.
Study Significance: This research provides a direct, imaging-based link between B-cell depletion and modulation of innate immune activity in the central nervous system, specifically targeting iron-rich microglia. For immunologists, it underscores the complex interplay between adaptive and innate immunity in neuroinflammation, moving beyond simple lymphocyte counts. The findings suggest that certain immunotherapies may have a broader mechanistic impact on myeloid cell function and tissue-level immunopathology, offering a new dimension for evaluating treatment efficacy in autoimmune and inflammatory conditions.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
